Investor Presentations Aclaris Therapeutics Presents ATI-450 Phase 2b Rheumatoid Arthritis Data Aclaris Therapeutics Company Overview – November 2023 Multiple Ascending Dose (MAD) Results of ATI-2138 (Investigational Novel Covalent ITK-JAK3 Inhibitor) – September 2023 Aclaris Therpeutics Q1 2023 Financial Results Presentation
Multiple Ascending Dose (MAD) Results of ATI-2138 (Investigational Novel Covalent ITK-JAK3 Inhibitor) – September 2023